Atezolizumab + bevacizumab
Checked 2026-09-09
Unresectable hepatocellular carcinoma, Child-Pugh A, varices treated
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Atezolizumab Monoclonal antibody (anti-PD-L1) | 1,200 mg | IV | D1 | |
Bevacizumab Monoclonal antibody (anti-VEGF) | 15 mg/kg | IV | D1 |
Cycles
until progression
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Endoscopy for varices within 6 months before starting; bleeding risk with bevacizumab.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.